Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 77 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF103659 NCT00338247

Last Modified: 6/12/2008 First Published: 5/28/2004


2.		Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				GSK-EGF30008 UCLA-0311034-01, NCT00073528


3.		ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF104383 NCT00272987


4.		Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF104535 NCT00281658

Last Modified: 9/19/2008 First Published: 10/14/2006


5.		Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-40302 CALGB-40302, NCT00390455


6.		Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF105485 NCT00374322


7.		Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Pharmaceutical / Industry				EGF102988 NCT00424255


8.		A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				NSABP B-41 NCT00486668


9.		Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				20 and over				Pharmaceutical / Industry				104578 NCT00486954


10.		ALTTO(Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation)Study; BIG 2-06/N063D

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				EGF106708 BIG 2-06/N063D/MAC13, NCT00490139

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute